Home \ Ophthalmology \ Mexidol® for glaucoma and age-related macular degeneration

Mexidol® with glaucoma and age -related macular degeneration

The brain in focus of arterial hypertension

Peculiarities of managing elderly patients

The brain is a key target organ for treatment of cerebrovascular risks

Mexidol as a geroprotector: potential and prospects

Neuroprotection in arterial hypertension and cognitive impairment

The Connection Between Vascular Diseases of the Brain and Eye: A Neurologist and Ophthalmologist's Perspective

Ischemic stroke: clinical guidelines and practical aspects

NIHSS and mRS: Gold Standards in Neuroscience

Cognitive impairment caused by arterial hypertension: from clinical guidelines to practical algorithms

The brain is a target organ for arterial hypertension: features of management of the elderly patient

Time codes:

00:00
Glaucoma and glaucoma optical neurocytopathy
01:01
Age -related macular degeneration of retina
01:18
The statistics of the incidence
01:59
Similarities and differences between glaucoma and macular degeneration of the retina
02:20
Retinoprotection and use of Mexidol®

Egorov Evgeniy Alekseevich – Doctor of Medical Sciences, Professor, President of the Russian Glaucoma Society, Head. Department of Ophthalmology named after. Academician A.P. Nesterov RNRMU named after. N.I. Pirogov

Announcement:

Glaucoma is the silent killer of the optic nerve. Its main danger is that it often progresses unnoticed by the patient and can progress without affecting intraocular pressure. Another dreaded disease is age-related macular degeneration. It affects the center of the macula in the retina, which is responsible for clear vision. Glaucoma and age-related macular degeneration are two diseases that can lead to blindness. To preserve visual function in these conditions, retinoprotection—protecting the retina—is crucial. hasMexidol® for glaucoma and other optic nerve lesions of any severity.

Learn more in the video "Glaucoma and Age-Related Macular Degeneration in Clinical Practice."

All videos Next video

The brain in focus of arterial hypertension

Peculiarities of managing elderly patients

The brain is a key target organ for treatment of cerebrovascular risks

Mexidol as a geroprotector: potential and prospects

Neuroprotection in arterial hypertension and cognitive impairment

The Connection Between Vascular Diseases of the Brain and Eye: A Neurologist and Ophthalmologist's Perspective

Ischemic stroke: clinical guidelines and practical aspects

NIHSS and mRS: Gold Standards in Neuroscience

Cognitive impairment caused by arterial hypertension: from clinical guidelines to practical algorithms

The brain is a target organ for arterial hypertension: features of management of the elderly patient

Time codes:

00:00
Glaucoma and glaucoma optical neurocytopathy
01:01
Age -related macular degeneration of retina
01:18
The statistics of the incidence
01:59
Similarities and differences between glaucoma and macular degeneration of the retina
02:20
Retinoprotection and use of Mexidol®

Block of articles on this topic

The effect of antioxidant therapy on some pathogenetic factors of primary open -angle glaucoma

Authors:
T.N. MALISHEVSKAYA¹, Yu.E. FILIPPOVA²

¹Federal State Budgetary Institution "Helmholtz National Medical Research Center for Eye Diseases" of the Ministry of Health of the Russian Federation, Moscow, Russia;
²State Autonomous Healthcare Institution of the Tyumen Region "Regional Ophthalmological Dispensary", Tyumen, Russia

Mexidol in the complex treatment of glaucoma

Author:
E.A. EGOROV, N.G. DAVYDOVA, I.A. ROMANENKO, N.D. NOVIKOVA

RNIMU named after N.I. Pirogov, GB of GB named after Helmholtz, Moscow

The possibilities and results of the use of antioxidant therapy in ophthalmological practice

Authors:
A.B. MOVSISYAN^1,2, Zh.G. OGANEZOVA^2,3, E.A. EGOROV²

¹Hospital for War Veterans No. 2 of the Moscow Health Department, Moscow, Russia;
²Pirogov Russian National Research Medical University, Moscow, Russia;
³Bochkov Medical Genetic Research Center, Moscow, Russia

The experience of neuroprotective therapy of primary open -angle glaucoma based on the use of various forms of Mexidol

Authors:
E.S. LEONOVA^1,2, S.V. POLYAKOV^1,2, M.A. POZDNYAKOVA², E.P. YARYGINA³, S.O. SEMISYNOV²

^1.NGO "Road Clinical Hospital at Gorky Station of JSC "Russian Railways", Inter-Road Ophthalmology Center
^2.State Budgetary Educational Institution of Higher Professional Education "Nizhny Novgorod State Medical Academy"
^3.State Budgetary Healthcare Institution of the Nizhny Novgorod Region "City Hospital No. 35", City Glaucoma Center

The use of Mexidol in the treatment of primary open -angle glaucoma

Authors:
I.A. LOSKUTOV, O.M. ANDRYUKHINA, A.A. KOVRIZHKINA

Moscow Regional Research Clinical Institute. M.F. Vladimir

THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.

Source of photos and images Shutterstock.com